The goal of Gedeon Richter Plc.'s business strategy for the period 2018-2028 is to become a prominent player in the league of European-based midpharma.
To this end, the product portfolio, the related know-how, infrastructure and commercial capabilities are constantly evolving, with an emphasis on high intellectual value-added products in addition to traditional and generic medicines. Consequently, Richter needs to focus its resources on areas where it has specialised knowledge: CNS disorders in original research, women's healthcare and biosimilar product development.
Our strategy sets clear directions for each element of our highly diversified product portfolio. Strategic pillars that take into account the different lifecycle characteristics of each product provide a unified framework for portfolio management. The pillars for the initial stage of a product's life cycle and which allow building in the long term are original research and biotechnology. The pillars representing the growth engine for the period 2018-2028 are the lifecycle management of Richter's proprietary blockbuster cariprazin and women's healthcare. The defensive leg of the strategy covers branded generics and the traditional portfolio.
Our strategy sets clear directions for each element of our highly diversified product portfolio. Strategic pillars that take into account the different lifecycle characteristics of each product provide a unified framework for portfolio management. The pillars for the initial stage of a product's life cycle and which allow building in the long term are original research and biotechnology. The pillars representing the growth engine for the period 2018-2028 are the lifecycle management of Richter's proprietary blockbuster cariprazin and women's healthcare. The defensive leg of the strategy covers branded generics and the traditional portfolio.
All pillars contribute to the successful implementation of our strategy and our mission to provide high-quality medicines worldwide at affordable prices.
